The model estimated symptom onset with a 1.62-year average error in a high-risk research cohort. It is not a clinical test, and its UK Biobank replication relied on approximated dates.
A longitudinal study of people at elevated genetic risk found a 19-protein panel could estimate when clinical ALS would emerge, but broader validation remains necessary.
The ninth curated release links more than 535,000 whole genomes with nearly 482,000 electronic health records and adds proteomics, RNA and long-read sequencing.